Pharmacy to Dose: The Critical Care Podcast Nick Peters

Thrombolytic Dosing in PE: Versus Series
Special Guest: Lauren Igneri, PharmD, BCPS, BCCCP, FCCM
 
05:20 – High-risk PE
23:00 – Intermediate-risk
37:10 – Cardiac arrest
52:30 – Closing arguments
57:15 – Bonus: TNK v. tPA
 
Reference List: https://pharmacytodose.files.wordpress.com/2024/04/thrombolytic-dosing-in-pe-references.pdf
 
PharmacyToDose.Com
@PharmacyToDose
PharmacyToDose@Gmail.com
Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: SEPSISPAM
Special Guest: Katherine Spezzano, PharmD, MBA, BCCCP @KatSpazPharmD
 
Katherine Spezzano joins to discuss the April Trial of the Week “High versus Low Blood-Pressure Target in Patients with Septic Shock” the SEPSISPAM study, published in NEJM in 2014.
We set the scene by reviewing the concept of autoregulation, guideline recommendations, and pre-SEPSISPAM research assessing BP goals in sepsis. Then we do a deep dive into the SEPSISPAM trial of the week. Would we see these same results with other vasopressors? Did each group meet their BP goal range? How do we balance AKI prevention and longer ICU LOS? What do our guidelines recommend now? Trial fun facts, alternate trial acronym ideas, and much more!
 
Reference list: https://pharmacytodose.files.wordpress.com/2024/04/sepsispam-trial-of-the-week-references.pdf
 
PharmacyToDose.Com
@PharmacyToDose
PharmacyToDose@Gmail.com
Learn more about your ad choices. Visit megaphone.fm/adchoices

Glycemic Control in the Critically Ill: Part II
Special Guests: Judi Jacobi, PharmD, FCCP, MCCM, BCCCP @JudiJacobi
Michael Sirimaturos, PharmD, BCNSP, BCCCP, FCCM @MSirimaturos
 
04:10 – Becoming panel members
11:50 – Guideline scope and PICO questions
21:35 – 2012 v. 2024 guidelines
28:05 – Effect of TGC-FAST
30:40 – 2024 guideline deep-dive
42:00 – Clinical decision support tools
50:00 – Pediatric recommendations
54:40 – Important future research topics
66:05 – Guideline manuscript writing
76:10 – Take-home points
 
Reference List: https://pharmacytodose.files.wordpress.com/2024/04/glycemic-control-in-the-icu-part-ii-references.pdf
 
PharmacyToDose.Com
@PharmacyToDose
PharmacyToDose@Gmail.com
Learn more about your ad choices. Visit megaphone.fm/adchoices

Literature Review Series
November 2023
Special Guests: Arjay Mendoza, PharmD, BCPS, AAHIVP
Brock Townsend, PharmD @Townsend_PharmD
 
04:30 – Featured Articles
35:25 – Cardiology
48:05 – Precision-based medicine potpourri
58:50 – Infectious Diseases
69:10 – PharmD
 
Reference List: https://pharmacytodose.files.wordpress.com/2024/04/november-lrs-2023-references.pdf
 
PharmacyToDose.Com
@PharmacyToDose
PharmacyToDose@Gmail.com
Learn more about your ad choices. Visit megaphone.fm/adchoices

Trial of the Week: SOAP II
Special Guest: Jessica Casey, PharmD, BCPS, BCCP @jmc_cardspharmd
 
Jessica Casey joins to discuss the April Trial of the Week “Comparison of Dopamine and Norepinephrine in the Treatment of Shock,” the SOAP II study, published in NEJM in 2010.
We set the scene by reviewing catecholamine vasopressor receptor physiology, guideline recommendations, and pre-SOAP II research. Then we do a deep dive into the SOAP II trial of the week. Did including all forms of shock help or hurt? How does the mortality in this study compare with others? Would this have been as positive of a study in 2024? What do the guidelines recommend now? Is dopamine dead? Will anyone take norepinephrine’s throne? Jessica and I review trial fun facts, stand-out supplementary materials, and much, much more.
 
Reference list: https://pharmacytodose.files.wordpress.com/2024/04/soap-ii-trial-of-the-week-references.pdf
 
PharmacyToDose.Com
@PharmacyToDose
PharmacyToDose@Gmail.com
Learn more about your ad choices. Visit megaphone.fm/adchoices

Trials of the Week: Landmark Nimodipine Studies
Special Guest: Salia Farrokh, PharmD, BCCCP, FNCS @salia_farrokh
 
Salia Farrokh joins to highlight two landmark studies with nimodipine, “Cerebral Arterial Spasm – A Controlled Trial of Nimodipine in Patients with Subarachnoid Hemorrhage” published in NEJM in 1983 and “Effect of Oral Nimodipine on Cerebral Infarction and Outcome after Subarachnoid Hemorrhage: British Aneurysm Nimodipine Trial” published in 1989 in BMJ.
We review aSAH treatments in the 1970’s and 1980’s and what evidence existed for nimodipine use before highlighting our two trials of the week. How does the study methodology compare from then to now? Where did our nimodipine dosing regimen come from? Is the term cerebral artery vasospasm out of date? Is it still appropriate to use evidence from the 1980’s in the 2020’s? Is there more to research with respect to nimodipine? What to do with missed nimodipine doses? We do a deep dive into all things nimodipine for aSAH, discussing the above and much more.
 
Reference list:  https://pharmacytodose.files.wordpress.com/2024/04/nimodipine-trial-of-the-week-references.pdf
 
PharmacyToDose.Com
@PharmacyToDose
PharmacyToDose@Gmail.com
Learn more about your ad choices. Visit megaphone.fm/adchoices